Anticoagulant threpy for patients with obstetric antiphospholipid syndrome.
Phase 2
Recruiting
- Conditions
- Antiphospholipid syndrome
- Registration Number
- JPRN-jRCTs041180093
- Lead Sponsor
- Sugiura Mayumi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Two or more early miscarriage
One or more fetal death
Preterm birth <34 weeks' gestation caused by preeclampsia or placental dysfunction
Antiphospholipid antibodies continue positive for 12 weeks.
Exclusion Criteria
abnormal chromosome in either partner
uterine anomaly
bleeding disease, renal dysfunction, liver dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ive birth rate
- Secondary Outcome Measures
Name Time Method The frequency of heparin-induced thrombocytopenia, osteoporosis, liver dysfunction
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie anticoagulant therapy efficacy in obstetric antiphospholipid syndrome?
How does anticoagulant therapy in JPRN-jRCTs041180093 compare to standard-of-care treatments for obstetric APS?
What biomarkers are used for patient selection in anticoagulant therapy for obstetric antiphospholipid syndrome?
What are the potential adverse events associated with anticoagulant therapy in obstetric APS patients?
Are there any combination approaches or competitor drugs for anticoagulant therapy in obstetric antiphospholipid syndrome?